Results 141 to 150 of about 301,643 (264)

Achieving Language Justice in Pediatric Hematology‐Oncology: A Multinational Perspective for Language‐Concordant Equitable Patient‐ and Family‐Centered Care and Research Inclusion

Pediatric Blood &Cancer, Volume 72, Issue 4, April 2025.
ABSTRACT Language‐discordant healthcare encounters—when the patient/caregiver and clinician are not able to communicate directly in the patient's/caregiver's preferred language—are associated with worse quality of care, increased adverse events, and research exclusion.
Jenny Ruiz, Joanna M. Robles, Luisanna M. Sánchez, Alisa Khan, Amy D. Lu, Stacey Marjerrison, Andres Morales La Madrid, Paula Aristizabal   +7 more
wiley   +1 more source

Current status of treatment and disease burden of a cohort of hemophilia B in China. [PDF]

Front Public Health, 2023
Huang Y, Wan C, Guan T, Xi X.
europepmc   +1 more source

Discussion:Future Considerations in the Management of Hemophilia B [PDF]

, 1995

openalex   +1 more source

ISUOG/ESGO Consensus Statement on ultrasound‐guided biopsy in gynecological oncology

Ultrasound in Obstetrics &Gynecology, Volume 65, Issue 4, Page 517-535, April 2025.
ABSTRACT The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) with the European Society of Gynaecological Oncology (ESGO) jointly developed clinically relevant and evidence‐based statements on performing ultrasound‐guided biopsies in gynecological oncology.
D. Fischerova, F. Planchamp, J. L. Alcázar, P. Dundr, E. Epstein, A. Felix, F. Frühauf, G. Garganese, I. Salvesen Haldorsen, D. Jurkovic, R. Kocian, D. Lengyel, F. Mascilini, A. Stepanyan, M. Stukan, S. Timmerman, T. Vanassche, Z. Yuan Ng, U. Scovazzi   +18 more
wiley   +1 more source

Nine independentF9 mutations in the Mexican hemophilia B population: Nonrandom recurrences of point mutation events in the human germline [PDF]

, 2000
Ana Rebeca Jaloma‐Cruz, William A. Scaringe, Joni B. Drost, Stacy Roberts, Xuemin Li, Patricio Barros-N��ez, Luis E. Figuera, Fernando Rivas, Jos� Mar�a Cant�, Steve S. Sommer   +9 more
openalex   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Identification of Risk Factors and Predictive Indicators for Tigecycline‐Associated Hypofibrinogenemia

Clinical and Translational Science, Volume 18, Issue 4, April 2025.
ABSTRACT To investigate the prevalence, clinical manifestations, and risk factors of hypofibrinogenemia after tigecycline use, which can disrupt coagulation and potentially hinder antimicrobial therapy. This observational study was conducted from January to December 2021 at a tertiary general hospital in China.
Xiaohui Liu, Xuefeng Yuan, Long Wen, Xin Tan, Qian Sui, Jiheng Liu   +5 more
wiley   +1 more source

Sustained and Complete Phenotype Correction of Hemophilia B Mice Following Intramuscular Injection of AAV1 Serotype Vectors [PDF]

, 2001
Hengjun Chao, Paul E. Monahan, Yuanbo Liu, R. Jude Samulski, Christopher Walsh   +4 more
openalex   +1 more source

The Edges of Clinical Pharmacology: A Narrative Review on Religious and Sociocultural Influences in Drug Management

Clinical and Translational Science, Volume 18, Issue 4, April 2025.
ABSTRACT Scientific advancements in pharmacology have revolutionized disease management, significantly enhancing global health. Innovations like biological therapies and mRNA vaccines underscore the field's capacity to address complex conditions and global crises.
Salvatore Di Maria, Alessio Provenzani
wiley   +1 more source

Hemophilia B: A Pain in the Back. [PDF]

Cureus, 2023
Vedire A, Upadrasta G, Imburgio S, Johal AS, Hossain MA.   +4 more
europepmc   +1 more source